Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC1405842397;42398;42399 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
N2AB1241737474;37475;37476 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
N2A1149034693;34694;34695 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
N2B499315202;15203;15204 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
Novex-1511815577;15578;15579 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
Novex-2518515778;15779;15780 chr2:178634609;178634608;178634607chr2:179499336;179499335;179499334
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: V
  • RefSeq wild type transcript codon: GTG
  • RefSeq wild type template codon: CAC
  • Domain: Ig-91
  • Domain position: 5
  • Structural Position: 5
  • Q(SASA): 0.3452
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
V/M rs774014126 -0.276 0.999 N 0.545 0.267 0.479818277033 gnomAD-2.1.1 4.03E-06 None None None None N None 0 0 None 0 0 None 0 None 0 8.91E-06 0
V/M rs774014126 -0.276 0.999 N 0.545 0.267 0.479818277033 gnomAD-4.0.0 1.5925E-06 None None None None N None 0 0 None 0 0 None 0 0 2.8604E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
V/A 0.2803 likely_benign 0.332 benign -1.191 Destabilizing 0.953 D 0.482 neutral N 0.507265823 None None N
V/C 0.878 likely_pathogenic 0.8838 pathogenic -0.705 Destabilizing 1.0 D 0.613 neutral None None None None N
V/D 0.4915 ambiguous 0.5709 pathogenic -0.978 Destabilizing 0.171 N 0.393 neutral None None None None N
V/E 0.3222 likely_benign 0.3623 ambiguous -1.01 Destabilizing 0.961 D 0.515 neutral N 0.476810875 None None N
V/F 0.2522 likely_benign 0.298 benign -0.939 Destabilizing 0.999 D 0.61 neutral None None None None N
V/G 0.4278 ambiguous 0.4795 ambiguous -1.467 Destabilizing 0.99 D 0.553 neutral N 0.50734225 None None N
V/H 0.6895 likely_pathogenic 0.7299 pathogenic -0.963 Destabilizing 1.0 D 0.658 neutral None None None None N
V/I 0.0918 likely_benign 0.0957 benign -0.552 Destabilizing 0.985 D 0.467 neutral None None None None N
V/K 0.4391 ambiguous 0.471 ambiguous -1.032 Destabilizing 0.998 D 0.561 neutral None None None None N
V/L 0.2712 likely_benign 0.3011 benign -0.552 Destabilizing 0.953 D 0.487 neutral N 0.508913938 None None N
V/M 0.1967 likely_benign 0.2214 benign -0.387 Destabilizing 0.999 D 0.545 neutral N 0.507258065 None None N
V/N 0.3714 ambiguous 0.4176 ambiguous -0.766 Destabilizing 0.996 D 0.655 neutral None None None None N
V/P 0.9262 likely_pathogenic 0.9468 pathogenic -0.729 Destabilizing 0.999 D 0.646 neutral None None None None N
V/Q 0.3744 ambiguous 0.4003 ambiguous -0.966 Destabilizing 0.998 D 0.643 neutral None None None None N
V/R 0.4321 ambiguous 0.489 ambiguous -0.463 Destabilizing 0.998 D 0.669 neutral None None None None N
V/S 0.3007 likely_benign 0.3414 ambiguous -1.234 Destabilizing 0.971 D 0.529 neutral None None None None N
V/T 0.239 likely_benign 0.2482 benign -1.163 Destabilizing 0.469 N 0.259 neutral None None None None N
V/W 0.9261 likely_pathogenic 0.9443 pathogenic -1.103 Destabilizing 1.0 D 0.668 neutral None None None None N
V/Y 0.6907 likely_pathogenic 0.7281 pathogenic -0.822 Destabilizing 0.999 D 0.62 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.